000			02033nam a2200397 i 4500
001			2133344
003			StDuBDS
005			20240729133142.0
006			m|||||o||d||||||||
007			cr |||||||||||
008			200131s2020 enka fob 001|0|eng|d
020			_a9781912776221 (PDF ebook) : _cNo price
020			_z9781912776214 (pbk.) : _cNo price
020			_z9781912776221
040			_aStDuBDS _beng _cStDuBDS _erda _epn
060		4	_aQV 4
100	1		_aCornes, Paul _c(Oncologist), _eauthor.
245	1	0	_aBiosimilars in hematology and oncology / _h[E-Book]
264		1	_aAbingdon, Oxford : _bKarger, _c2020.
300			_a1 online resource (128 pages) : _billustrations (black and white, and colour).
490	1		_aFast facts
500			_aAlso issued in print: 2020.
504			_aIncludes bibliographical references and index.
520	8		_aBiologics have revolutionised - and are revolutionising - the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars - particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients.
521			_aSpecialized.
588			_aDescription based on online resource; title from PDF title page (viewed on January 17, 2023).
650		0	_aPharmaceutical biotechnology.
650		0	_aHematology.
650		0	_aOncology. _913364
650		2	_aTechnology, Pharmaceutical.
650		2	_aHematology.
650		2	_aMedical Oncology.
700	1		_aMcBride, Ali, _eauthor.
830		0	_aFast facts.
856			_u#gotoholdings _yAccess resource
999			_c96844 _d96844